Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F17%3A00118655" target="_blank" >RIV/00216224:14110/17:00118655 - isvavai.cz</a>

Alternative codes found

RIV/00209805:_____/17:00077805

Result on the web

<a href="https://www.linkos.cz/casopis-klinicka-onkologie/2017-12-14-s3/checkpoint-inhibitory-v-lecbe-nadoru-horniho-gastrointestinalniho-traktu/" target="_blank" >https://www.linkos.cz/casopis-klinicka-onkologie/2017-12-14-s3/checkpoint-inhibitory-v-lecbe-nadoru-horniho-gastrointestinalniho-traktu/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.14735/amko20173S50" target="_blank" >10.14735/amko20173S50</a>

Result language

čeština

Original language name

Checkpoint inhibitory v léčbě nádorů horního gastrointestinálního traktu

Original language description

Chemotherapy prolongs overall survival (OS) in esophageal (EC) and gastric cancer (GC). Unsatisfactory results of systemic therapy initiated a search for new treatment options. In metastatic disease, a number of targeted drugs were tested; however, several phase III studies assessing receptor tyrosin kinase-related signaling pathways, such as EGFR, MET/HGF or mTOR, failed. Trastuzumab remains the only targeted drug with a known molecular predictor, which extended the OS in metastatic gastric adenocarcinoma and adenocarcinoma of esophago-gastric junction. In the past two years, The Cancer Genome Atlas group published an analysis based on the genomic characteristics of GC and EC. Therefore, a better understanding of tumor biology may be a way towards stratification of treatment based on genetic and molecular characteristics and not merely on anatomical or histological basis. The rapid development in research of anti-tumor immunity and an achievement in the field of checkpoint inhibitors use in malignant melanoma have also enabled research in other cancers, including gastrointestinal malignancies. Checkpoints are part of a comprehensive and complex process of the immune system, and at the same time, the key points in the emergence of tumor tolerance. Their activation protects the organism against autoimmune reactions, but at the same time allows induction of tumor tolerance. Discussing checkpoints include the cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1) receptors and the ligand PD-1 receptor, programmed death ligand-1 (PD-L1). In this article, I summarize current findings on the use of anti PD1 agents in EC and GC

Czech name

Checkpoint inhibitory v léčbě nádorů horního gastrointestinálního traktu

Czech description

Chemotherapy prolongs overall survival (OS) in esophageal (EC) and gastric cancer (GC). Unsatisfactory results of systemic therapy initiated a search for new treatment options. In metastatic disease, a number of targeted drugs were tested; however, several phase III studies assessing receptor tyrosin kinase-related signaling pathways, such as EGFR, MET/HGF or mTOR, failed. Trastuzumab remains the only targeted drug with a known molecular predictor, which extended the OS in metastatic gastric adenocarcinoma and adenocarcinoma of esophago-gastric junction. In the past two years, The Cancer Genome Atlas group published an analysis based on the genomic characteristics of GC and EC. Therefore, a better understanding of tumor biology may be a way towards stratification of treatment based on genetic and molecular characteristics and not merely on anatomical or histological basis. The rapid development in research of anti-tumor immunity and an achievement in the field of checkpoint inhibitors use in malignant melanoma have also enabled research in other cancers, including gastrointestinal malignancies. Checkpoints are part of a comprehensive and complex process of the immune system, and at the same time, the key points in the emergence of tumor tolerance. Their activation protects the organism against autoimmune reactions, but at the same time allows induction of tumor tolerance. Discussing checkpoints include the cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1) receptors and the ligand PD-1 receptor, programmed death ligand-1 (PD-L1). In this article, I summarize current findings on the use of anti PD1 agents in EC and GC

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

<a href="/en/project/NV17-29389A" target="_blank" >NV17-29389A: Sequential FDG-PET and plasma and tissue miRNA as a biomarker of preoperative treatment strategy in locally advanced oesophagogastric cancer</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Klinická onkologie

ISSN

0862-495X

e-ISSN

1802-5307

Volume of the periodical

30

Issue of the periodical within the volume

S3

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

5

Pages from-to

„3S50“-„3S54“

UT code for WoS article

—

EID of the result in the Scopus database

2-s2.0-85038624812